Corporate Information

• 27 Aug, 2024
  Spago Nanomedicals fas I/IIa-studie Tumorad-01 fortsätter efter framgångsrikt slutförd behandling av första patientgruppen
• 27 Aug, 2024
  Spago Nanomedical’s Phase I/IIa study Tumorad-01 continues following successful treatment completion of first patient group
• 10 Jun, 2024
  Kommuniké från årsstämma 2024 i Spago Nanomedical AB
• 10 Jun, 2024
  Bulletin from the 2024 Annual General Meeting of Spago Nanomedical AB
• 20 May, 2024
  Spago Nanomedical uppdaterar om Tumorad-01 – studien framskrider enligt plan
• 20 May, 2024
  Spago Nanomedical provides an update on Tumorad-01 – trial proceeds as planned
• 6 May, 2024
  NOTICE TO ANNUAL GENERAL MEETING OF SPAGO NANOMEDICAL AB (PUBL)
• 6 May, 2024
  KALLELSE TILL ÅRSSTÄMMA I SPAGO NANOMEDICAL AB (PUBL)
• 24 Apr, 2024
  Spago Nanomedical rapporterar gynnsamma data i bröstcancermodell med Tumorad
• 24 Apr, 2024
  Spago Nanomedical reports favorable data in breast cancer model with Tumorad